27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Choline acetyltransferase activity (presynaptic cholinergic system) and high affinity binding of cholinergic antagonists (postsynaptic cholinergic system) were measured in brain tissue removed after death from both mentally normal and demented old people. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The CES-D scale is a short self-report scale designed to measure depressive symptomatology in the general population. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Why assessment is of practical consequence to anaesthetistsGeneral Health Questionnaire (GHQ) in general hospitals: selecting a set of items using a stepwise hierarchical procedurePain assessment in cognitively impaired and unimpaired older adults: a comparison of four scalesMental disorders among internal medical inpatientsSuicide in Later Life: A Review and Recommendations for PreventionDELIRIUM IN THE TERMINALLY ILLRecognition of psychiatric disorders in nonpsychiatric hospital wardsNursing documentation versus standardized assessment of cognitive status in hospitalized medical patientsCompleted Suicide Among Older Patients in Primary Care Practices: A Controlled StudyDoes myasthenia gravis affect the brain?SUICIDAL PATIENTS IN THE ED: ETHICAL ISSUESMethodological issues of an epidemiological study: From the results of a study on psychological problems seen in outpatients visiting the internal medicine departments of general hospitalsPsychiatric disorders and vertigoTotal Quality Management and Geriatric CareAssessment and treatment of depression in the cancer patientUse of hospital services by AIDS patients with psychiatric illnessNeuropsychological and Pharmacokinetic Assessment of Hospice Inpatients Receiving MorphineMANAGEMENT OF SUICIDAL BEHAVIOR IN THE ELDERLYLiteraturverzeichnisSuicide in later lifeMajor depression in the primary care settingMaking the diagnosis of depression in the primary care settingThe Mini-Mental State Examination in General Medical Practice: Clinical Utility and AcceptancePsychological Morbidity in Obstetric-Gynaecology Patients: Testing the Need for Expanded Psychiatry Services in Obstetric-Gynaecology FacilitiesPrevalence of Psychiatric Disorders in Medical InpatientsTranstornos do humor em enfermaria de clínica médica e validação de escala de medida (HAD) de ansiedade e depressãoDelirium in Elderly Patients: Evaluation and ManagementDelirium Presenting With Symptoms of DepressionAnalysis of the terms used by general practitioners to characterize patients considered by them as depressed.
Participants: 100 Evidence: low
Full summary, score breakdown and related studies → Original source
Nine members of a family spanning three generations showed bilateral calcifications of the basal ganglia with autosomal dominant inheritance. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A sequential light and electron microscopic study of cerebral cortex was performed in a rat model of portal-systemic encephalopathy produced by creating a portacaval shunt and followed by ammoniate resin feedings. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The cases of six patients are presented to delineate the clinical profile of delayed radiation necrosis of the brain. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Reductions in 2 neurotransmitter synthesizing enzymes in brain, glutamic acid decarboxylase (GAD) and choline acetyltransferase (CAT), have been found in dementias of different origins, including senile dementia (Alzheimer type). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →